Clinical trials: GLP-1
GLP-1, Gut Microbiota
Effects of Sucralose in Gut Intestinal Microbiota and Postprandial GLP-1
Recently, it has been proposed that the consumption of non-nutritive sweeteners, including sucralose, it's not harmless and is related with metabolic effects.
- Conditions
- GLP-1, Gut Microbiota, Insulin Resistance
- Trial name
- NCT06094894
- Testing
- sucralose
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Obesity and Obesity-related Medical Conditions, Obesity and Overweight
MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
The purpose of this study is to assess the effect of gastric fundal mucosal ablation (GFMA) on weight trajectory following discontinuation of once-weekly semaglutide or tirzepatide in adults with obesity.
- Conditions
- Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism
- Trial name
- MAINTAIN (NCT06734312)
- Testing
- Gastric Fundal Mucosal Ablation (GFMA)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dr. Christopher McGowan
Diabetes, SGLT-2i and GLP-1RA Therapies
Addressing Diffusion of Responsibility and Prescribing Burden to Improve Use of Diabetes Medications
This study will test the impact of addressing diffusion of responsibility with and without additional reduction of prescribing burden on SGLT-2i and GLP-1RAs prescribing compared to usual care.
- Conditions
- Diabetes, SGLT-2i and GLP-1RA Therapies, Diffusion of Responsibility, Prescribing Burden
- Trial name
- NCT05463705
- Testing
- Intervention to address diffusion of responsibility, Intervention to address diffusion of responsibility + simplification of prescribing
- Where
- United States
- Volunteers
- 1,580 people
- Sponsor
- Brigham and Women's Hospital
Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying
GLP_1 RA Ultrasound Study
The purpose of the study is to determine whether patients taking GLP-1 RAs have increased residual (left behind), gastric (stomach), contents due to delayed gastric emptying when following standard preoperative fasting guidelines.
- Conditions
- Glucagon Like Peptide-1 (GLP-1, Delayed Gastric Emptying, Risk of Aspiration, Diabetes
- Trial name
- NCT06581120
- Testing
- Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Metabolic Disturbance, Schizophrenia
Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
Background and objective: Clozapine and olanzapine are some of the most effective antipsychotic drugs, but unfortunately, both drugs induce weight gain and conveys a high degree of metabolic disturbances.
- Conditions
- Metabolic Disturbance, Schizophrenia, Type 2 Diabetes, Clozapine
- Trial name
- NCT04892199
- Testing
- Semaglutide, 1.34 mg/mL
- Where
- 3 sites in Denmark
- Volunteers
- 104 people
- Sponsor
- Anders Fink-Jensen, MD, DMSci
Diabetes, Gastric Content Aspiration
Effects of GLP-1 Agonists on Gastric Volume
This study will enroll patients ages 18 and over who have a diagnosis of diabetes, are undergoing an elective surgery under general anesthesia and 1) are taking a GLP-1 receptor agonist medication, or 2) not taking a GLP-1…
- Conditions
- Diabetes, Gastric Content Aspiration, Glucagon-like Peptide 1, GLP-1
- Trial name
- NCT05854979
- Testing
- Gastric Ultrasound
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Medical University of South Carolina
GLP-1 Concentration
The Dose Response of Calcium Co-ingested With Protein on GLP-1 Concentrations
Hormones that are produced by our stomach and intestines play a role in regulating our appetite and health. One of the most important hormones is called GLP-1.
- Trial name
- PROCAL (NCT03819972)
- Testing
- Dose response of Capolac®
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Bath
The GLP-1-mediated Gut-kidney Axis
Acute Effects of GLP-1 on Renal Hemodynamics
This study investigates the hypothesis, that GLP-1's suppression of ANG II and natriuretic action increase medullary perfusion and decrease oxygen consumption, leading to higher tissue oxygenation.
- Trial name
- GLP1RRBF (NCT04337268)
- Testing
- Glucagon-Like Peptide 1, saline 0.9%
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
PYY, Ghrelin
The Comparison of PYY, Ghrelin, GLP1, Glucose Level, Level of Satiety, and Ad Libitum Intake in Obese and Non-Obese Patients After Breakfast With Balanced Macronutrient Composition
Obesity can occur due to an imbalance of energy. This energy balance is greatly influenced by hunger and satiety. Obese person cannot resist hunger, while non obese can control hunger.
- Conditions
- PYY, Ghrelin, Appetite, Gut Hormones
- Trial name
- NCT03701503
- Testing
- Diet with balance composition to know the effect of a meal to gut hormones in obese and non obese women
- Where
- Indonesia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universitas Indonesia
Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1
Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
This study was to investigate the Effect of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, on progression of coronary atherosclerosis in patients with type 2 diabetes.
- Trial name
- NCT03602638
- Testing
- Sitagliptin, Acarbose
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
GLP-1；Metformin；Telomere-telomerase System；Par-4
Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment
Objectives: To investigate the treatment effect between insulin,metformin and Liraglutide; in Type 2 Diabetes in our hospital, in order to investigate the possible mechanism about telomere-telomerase system and Par-4.
- Trial name
- Par-4；GLP-1 (NCT02535299)
- Testing
- Liraglutide, Metformin
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Third Military Medical University
Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1
Dose-response Study of Exendin-9,39 on Glucose Metabolism
Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min.
- Trial name
- NCT01218633
- Testing
- saline infusion, GLP-1-9,36 infusion, Exendin-9,39 at low dose
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Adrian Vella
The Focus of This Study is to Evaluete the Significances of the Vagal Cholinerg Nervuos System for the Effect of GLP-1 by Using Atropin Administration.
Atropin and Glucose Stimulated Insulinsecretion and the Cephalic Insulin Response
The aim of this study is to investigate the role of transmission of vagal cholinerg for the GLP-1 potentiation of the glucose stimulated insulin secretion and the cephalic insulin response by using atropin administration.
- Trial name
- NCT01534442
- Testing
- Atropine
- Where
- 2 sites in Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen